SCHEMBL1459983

SCHEMBL1459983

O=C1Cc2ccccc2N1I

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.56
HPGD P15428 1/20 0.55
DDB1 Q16531 1/20 0.46
CRBN Q96SW2 1/20 0.46
CASP3 P42574 1/20 0.42
CASP6 P55212 1/20 0.42
KMT2A Q03164 1/20 0.42
SENP8 Q96LD8 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
SENP6 Q9GZR1 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
OPRM1 P35372 4/20 0.41
OPRK1 P41145 4/20 0.41
OPRL1 P41146 4/20 0.41
HTR7 P34969 3/20 0.41
CHRNB4 P30926 1/20 0.41
CHRNA3 P32297 1/20 0.41
RNASEH1 O60930 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2A6 P11509 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30642100 1.00 NOTUM (0.56) NOTUMHPGDDDB1CRBNCASP3
SCHEMBL4412240 0.84 KMT2A (0.49) NOTUMHPGDDDB1CRBNCASP3
SCHEMBL20776999 0.81 NOTUM (0.44) NOTUMHPGDDDB1CRBNKMT2A
SCHEMBL29765632 0.77 HPGD (0.59) NOTUMHPGDDDB1CRBNCASP3
SCHEMBL21311764 0.76 KMT2A (0.57) NOTUMHPGDDDB1CRBNCASP3
SCHEMBL3641405 0.76 HPGD (0.57) NOTUMHPGDDDB1CRBNCASP3
SCHEMBL30642159 0.76 HPGD (0.57) NOTUMHPGDDDB1CRBNCASP3
SCHEMBL1464486 0.76 HPGD (0.57) NOTUMHPGDDDB1CRBNCASP3
SCHEMBL28767800 0.75 NOTUM (0.73) NOTUMHPGDDDB1CRBNCASP3
SCHEMBL16181505 0.75 RNASEH1 (0.61) HPGDCASP3CASP6KMT2ASENP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017096045-A1 MULTIVALENT RAS BINDING COMPOUNDS KYRAS THERAPEUTICS, INC. (US) 2017-06-08 WO disclosed
EP-2809668-B1 4-(BENZOIMIDAZOL-2-YL)-THIAZOLE COMPOUNDS AND RELATED AZA DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2017-04-12 EP disclosed
EP-2480529-A1 INDOLE DERIVATIVES AS CRAC MODULATORS F. Hoffmann-La Roche AG (CH) 2012-08-01 EP disclosed
CN-102574788-A Indole derivatives as crac modulators HOFFMANN LA ROCHE 2012-07-11 CN disclosed
WO-2011036130-A1 INDOLE DERIVATIVES AS CRAC MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2011-03-31 WO disclosed
US-20110071150-A1 INDOLE DERIVATIVES AS CRAC MODULATORS ALAM MUZAFFAR 2011-03-24 US disclosed
CN-101675061-A pyrrolo-N-heterocyclic derivatives, process for their preparation and their use in medicine SHANGHAI HENGRUI PHARM CO LTD 2010-03-17 CN disclosed
WO-2007061695-A2 BICYCLIC SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2007-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110071150-A1 INDOLE DERIVATIVES AS CRAC MODULATORS ORAI1, RYR2, CACNA1E NOTUM 4095/4885HPGD 2285/4885DDB1 3602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.